TPG to acquire Par Pharma for $1.9 billion


Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

Par Pharma to buy Indian generics group Edict for $37.6 million plus debt


US generics and niche drug company Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement…

Asia-PacificEdict PharmaceuticalsGenericsMergers & AcquisitionsPar Pharmaceutical

Back to top